Stockreport

Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF - Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025- Topline data from PIPE-307 Phase 2 VISTA trial for [Read more]